The treatment of Hodgkin's disease: emphasizing programs at the Clinic Center, National Institutes of Health.
During the past 10--15 years there has been a dramatic improvement in the prognosis of patients with Hodgkin's diases. More than 80% of all patients now will live 5+ years, many of them free from disease. The well-recognized immediate complications of therapy discussed above, are insignificant compared to the tremendous improvement in patients' survival. The fact that they now probably will survive long enough to potentially be at risk of such long-term complications is a testament to the efficacy of modern-day aggressive therapy.
D000328:Adult; D001761:Bleomycin / Q000627:therapeutic use; D001853:Bone Marrow / Q000473:pathology; D002648:Child; D002986:Clinical Trials as Topic; D004359:Drug Therapy, Combination; D005260:Female; D006689:Hodgkin Disease / Q000473:pathology / Q000628:therapy*; D006801:Humans; D010535:Laparoscopy; D007813:Laparotomy / Q000379:methods; D008099:Liver / Q000473:pathology; D008198:Lymph Nodes / Q000473:pathology; D008297:Male; D008466:Mechlorethamine / Q000627:therapeutic use; D009316:National Institutes of Health (U.S.); D009378:Neoplasms, Multiple Primary / Q000209:etiology; D011241:Prednisone / Q000627:therapeutic use; D011344:Procarbazine / Q000627:therapeutic use; D011882:Radiotherapy, High-Energy / Q000379:methods; D013154:Spleen / Q000473:pathology; D013156:Splenectomy; D014481:United States; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D011344:Procarbazine; D008466:Mechlorethamine; D014750:Vincristine; D011241:Prednisone